Sickle Cell Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
겸상 적혈구증 치료 시장 : 조사 범위
TMR의 조사 보고서 '세계의 겸상 적혈구증 치료 시장'은 2024년부터 2034년까지 예측 기간에 있어서 시장의 지표에 관한 귀중한 인사이트를 얻기 위해, 과거뿐만 아니라 현재의 성장 동향과 기회에 대해서도 조사했습니다. 본 보고서는 2024년을 기준연도, 2034년을 예측연도로 하여 2018년부터 2034년까지 세계의 겸상 적혈구증 치료 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계의 겸상 적혈구증 치료 시장의 복합 연간 성장률(CAGR%)도 제공합니다.
이 보고서는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서 분석가는 KOL(Key Opinion Leader), 업계 리더, 오피니언 제조업체와의 인터뷰를 실시했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 자료 등을 참조하여 겸상 적혈구증 치료 시장을 추찰했습니다.
| 시장 현황 |
| 시장 규모(2023년) |
27억 달러 |
| 시장 규모(2034년) |
177억 달러 |
| CAGR |
18.5% |
이 보고서는 세계의 겸상 적혈구증 치료 시장 경쟁 구도를 조사했습니다. 세계의 겸상 적혈구증 치료 시장에서 사업을 전개하는 주요 기업이 확인되고 각 기업은 다양한 속성으로 프로파일 되고 있습니다. 기업 개요, 재무상황, 최근 동향, SWOT가 본 보고서에서 소개되고 있는 세계의 겸상 적혈구증 치료 시장에 있어서 기업의 속성입니다.
목차
제1장 서문
제2장 전제조건 및 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
- 서문
- 개요
- 시장 역학
- 세계의 시장 분석 및 예측(2020-2034년)
제5장 주요 인사이트
- 주요 산업 이벤트
- PEST 분석
- 파이프라인 분석
- 주요국 및 지역별 규제 시나리오
- Porter's Five Forces 분석
- 주요 국가별 상환 시나리오
- 가격 분석
- 제품 및 브랜드 분석
- 겸상 적혈구증의 역학
- 기술적 진보
- 공급망 분석
- 시장의 미충족 요구
제6장 세계의 시장 분석 및 예측 : 약제 클래스별
- 서문 및 정의
- 주요 조사 결과 및 발전
- 시장 매출 예측 : 약제 클래스별(2020-2034년)
- 대사 길항제
- 아미노산
- NSAIDs
- 단클론항체
- 기타
- 시장의 매력 분석 : 약제 클래스별
제7장 세계의 시장 분석 및 예측 : 질병별
- 서문 및 정의
- 주요 조사 결과 및 발전
- 시장 매출 예측 : 질환별(2020-2034년)
- 헤모글로빈 SS(HbSS)
- 헤모글로빈 SC(HbSC)
- 헤모글로빈(HbS) 베타 살라세미아
- 시장의 매력 분석 : 질병별
제8장 세계의 시장 분석 및 예측 : 연령별
- 서문 및 정의
- 주요 조사 결과 및 발전
- 시장 매출 예측 : 연령별(2020-2034년)
- 시장의 매력 분석 : 연령별
제9장 세계의 시장 분석 및 예측 : 투여 경로별
- 서문 및 정의
- 주요 조사 결과 및 발전
- 시장 매출 예측 : 투여 경로별(2020-2034년)
- 시장의 매력 분석 : 투여 경로별
제10장 세계의 시장 분석 및 예측 : 유통 채널별
- 서문 및 정의
- 주요 조사 결과 및 발전
- 시장 매출 예측 : 유통 채널별(2020-2034년)
- 시장의 매력 분석 : 유통 채널별
제11장 세계의 시장 분석 및 예측 : 지역별
- 주요 조사 결과
- 시장 매출 예측 : 지역별(2020-2034년)
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- 시장의 매력 분석 : 지역별
제12장 북미의 시장 분석 및 예측
제13장 유럽의 시장 분석 및 예측
제14장 아시아태평양의 시장 분석 및 예측
제15장 라틴아메리카의 시장 분석 및 예측
제16장 중동 및 아프리카의 시장 분석 및 예측
제17장 경쟁 구도
- 시장 기업 : 경쟁 매트릭스(기업 Tier 및 규모별)
- 시장 점유율 분석 : 기업별(2023년)
- 기업 프로파일
- Bristol-Myers Squibb Company
- Novartis AG
- Emmaus Medical, Inc.
- Bluebird bio Inc.
- Pfizer Inc.
- CRISPR Therapeutics
- F. Hoffmann-La Roche AG
- Vertex Pharmaceuticals Incorporated
- Agios Pharmaceuticals, Inc.
- GlycoMimetics
- Graphite Bio, Inc.
- Mylan NV
- Teva Pharmaceutical Industries Ltd.
- AstraZeneca
- Hikma Pharmaceuticals PLC
- Addmedica
AJY
Sickle Cell Disease Treatment Market - Scope of Report
TMR's report on the global sickle cell disease treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global sickle cell disease treatment market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global sickle cell disease treatment market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the sickle cell disease treatment market.
| Market Snapshot |
|---|
| Market Value in 2023 | US$ 2.7 Bn |
| Market Value in 2034 | US$ 17.7 Bn |
| CAGR | 18.5% |
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global sickle cell disease treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global sickle cell disease treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global sickle cell disease treatment market.
The report delves into the competitive landscape of the global sickle cell disease treatment market. Key players operating in the global sickle cell disease treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global sickle cell disease treatment market profiled in this report.
Key Questions Answered in Global sickle cell disease treatment Market Report:
- What is the sales/revenue generated by sickle cell disease treatment across all regions during the forecast period?
- What are the opportunities in the global sickle cell disease treatment market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2034?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Sickle Cell Disease Treatment Market - Research Objectives and Research Approach
The comprehensive report on the global sickle cell disease treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global sickle cell disease treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global sickle cell disease treatment market.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Sickle Cell Disease Treatment Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Segment Definition
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Sickle Cell Disease Treatment Market Analysis and Forecast, 2020-2034
- 4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
- 5.1. Key Industry Events
- 5.2. PEST Analysis
- 5.3. Pipeline Analysis
- 5.4. Regulatory Scenario by Key Countries/Regions
- 5.5. PORTER's Five Forces Analysis
- 5.6. Reimbursement Scenario by Key Countries
- 5.7. Pricing Analysis
- 5.8. Product/Brand Analysis
- 5.9. Epidemiology of Sickle Cell Disease
- 5.10. Technological Advancements
- 5.11. Supply Chain Analysis
- 5.12. Unmet Needs of the Market
6. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Drug Class
- 6.1. Introduction & Definition
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Drug Class, 2020-2034
- 6.3.1. Antimetabolites
- 6.3.2. Amino Acids
- 6.3.3. NSAIDs
- 6.3.4. Monoclonal Antibodies
- 6.3.5. Others
- 6.4. Market Attractiveness Analysis, by Drug Class
7. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Disease Type
- 7.1. Introduction & Definition
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Disease Type, 2020-2034
- 7.3.1. Hemoglobin SS (HbSS)
- 7.3.2. Hemoglobin SC (HbSC)
- 7.3.3. Hemoglobin (HbS) beta thalassemia
- 7.4. Market Attractiveness Analysis, by Disease Type
8. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Age-Group
- 8.1. Introduction & Definition
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast, by Age-Group, 2020-2034
- 8.3.1. Children
- 8.3.2. Adults
- 8.4. Market Attractiveness Analysis, by Age-Group
9. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Route of Administration
- 9.1. Introduction & Definition
- 9.2. Key Findings/Developments
- 9.3. Market Value Forecast, by Route of Administration, 2020-2034
- 9.3.1. Oral
- 9.3.2. Parenteral
- 9.4. Market Attractiveness Analysis, by Route of Administration
10. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Distribution Channel
- 10.1. Introduction & Definition
- 10.2. Key Findings/Developments
- 10.3. Market Value Forecast, by Distribution Channel, 2020-2034
- 10.3.1. Hospital Pharmacies
- 10.3.2. Retail Pharmacies
- 10.3.3. Online Pharmacies
- 10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Region
- 11.1. Key Findings
- 11.2. Market Value Forecast, by Region, 2020-2034
- 11.2.1. North America
- 11.2.2. Europe
- 11.2.3. Asia Pacific
- 11.2.4. Latin America
- 11.2.5. Middle East & Africa
- 11.3. Market Attractiveness Analysis, by Region
12. North America Sickle Cell Disease Treatment Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Market Value Forecast, by Drug Class, 2020-2034
- 12.2.1. Antimetabolites
- 12.2.2. Amino Acids
- 12.2.3. NSAIDs
- 12.2.4. Monoclonal Antibodies
- 12.2.5. Others
- 12.3. Market Value Forecast, by Disease Type, 2020-2034
- 12.3.1. Hemoglobin SS (HbSS)
- 12.3.2. Hemoglobin SC (HbSC)
- 12.3.3. Hemoglobin (HbS) beta thalassemia
- 12.4. Market Value Forecast, by Age-Group, 2020-2034
- 12.4.1. Children
- 12.4.2. Adults
- 12.5. Market Value Forecast, by Route of Administration, 2020-2034
- 12.5.1. Oral
- 12.5.2. Parenteral
- 12.6. Market Value Forecast, by Distribution Channel, 2020-2034
- 12.6.1. Hospital Pharmacies
- 12.6.2. Retail Pharmacies
- 12.6.3. Online Pharmacies
- 12.7. Market Value Forecast, by Country, 2020-2034
- 12.7.1. U.S.
- 12.7.2. Canada
- 12.8. Market Attractiveness Analysis
- 12.8.1. By Drug Class
- 12.8.2. By Disease Type
- 12.8.3. By Age-Group
- 12.8.4. By Route of Administration
- 12.8.5. By Distribution Channel
- 12.8.6. By Country
13. Europe Sickle Cell Disease Treatment Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Market Value Forecast, by Drug Class, 2020-2034
- 13.2.1. Antimetabolites
- 13.2.2. Amino Acids
- 13.2.3. NSAIDs
- 13.2.4. Monoclonal Antibodies
- 13.2.5. Others
- 13.3. Market Value Forecast, by Disease Type, 2020-2034
- 13.3.1. Hemoglobin SS (HbSS)
- 13.3.2. Hemoglobin SC (HbSC)
- 13.3.3. Hemoglobin (HbS) beta thalassemia
- 13.4. Market Value Forecast, by Age-Group, 2020-2034
- 13.4.1. Children
- 13.4.2. Adults
- 13.5. Market Value Forecast, by Route of Administration, 2020-2034
- 13.5.1. Oral
- 13.5.2. Parenteral
- 13.6. Market Value Forecast, by Distribution Channel, 2020-2034
- 13.6.1. Hospital Pharmacies
- 13.6.2. Retail Pharmacies
- 13.6.3. Online Pharmacies
- 13.7. Market Value Forecast, by Country/Sub-region, 2020-2034
- 13.7.1. Germany
- 13.7.2. UK
- 13.7.3. France
- 13.7.4. Italy
- 13.7.5. Spain
- 13.7.6. Rest of Europe
- 13.8. Market Attractiveness Analysis
- 13.8.1. By Drug Class
- 13.8.2. By Disease Type
- 13.8.3. By Age-Group
- 13.8.4. By Route of Administration
- 13.8.5. By Distribution Channel
- 13.8.6. By Country/Sub-region
14. Asia Pacific Sickle Cell Disease Treatment Market Analysis and Forecast
- 14.1. Introduction
- 14.2. Market Value Forecast, by Drug Class, 2020-2034
- 14.2.1. Antimetabolites
- 14.2.2. Amino Acids
- 14.2.3. NSAIDs
- 14.2.4. Monoclonal Antibodies
- 14.2.5. Others
- 14.3. Market Value Forecast, by Disease Type, 2020-2034
- 14.3.1. Hemoglobin SS (HbSS)
- 14.3.2. Hemoglobin SC (HbSC)
- 14.3.3. Hemoglobin (HbS) beta thalassemia
- 14.4. Market Value Forecast, by Age-Group, 2020-2034
- 14.4.1. Children
- 14.4.2. Adults
- 14.5. Market Value Forecast, by Route of Administration, 2020-2034
- 14.5.1. Oral
- 14.5.2. Parenteral
- 14.6. Market Value Forecast, by Distribution Channel, 2020-2034
- 14.6.1. Hospital Pharmacies
- 14.6.2. Retail Pharmacies
- 14.6.3. Online Pharmacies
- 14.7. Market Value Forecast, by Country/Sub-region, 2020-2034
- 14.7.1. China
- 14.7.2. Japan
- 14.7.3. India
- 14.7.4. Australia & New Zealand
- 14.7.5. Rest of Asia Pacific
- 14.8. Market Attractiveness Analysis
- 14.8.1. By Drug Class
- 14.8.2. By Disease Type
- 14.8.3. By Age-Group
- 14.8.4. By Route of Administration
- 14.8.5. By Distribution Channel
- 14.8.6. By Country/Sub-region
15. Latin America Sickle Cell Disease Treatment Market Analysis and Forecast
- 15.1. Introduction
- 15.2. Market Value Forecast, by Drug Class, 2020-2034
- 15.2.1. Antimetabolites
- 15.2.2. Amino Acids
- 15.2.3. NSAIDs
- 15.2.4. Monoclonal Antibodies
- 15.2.5. Others
- 15.3. Market Value Forecast, by Disease Type, 2020-2034
- 15.3.1. Hemoglobin SS (HbSS)
- 15.3.2. Hemoglobin SC (HbSC)
- 15.3.3. Hemoglobin (HbS) beta thalassemia
- 15.4. Market Value Forecast, by Age-Group, 2020-2034
- 15.4.1. Children
- 15.4.2. Adults
- 15.5. Market Value Forecast, by Route of Administration, 2020-2034
- 15.5.1. Oral
- 15.5.2. Parenteral
- 15.6. Market Value Forecast, by Distribution Channel, 2020-2034
- 15.6.1. Hospital Pharmacies
- 15.6.2. Retail Pharmacies
- 15.6.3. Online Pharmacies
- 15.7. Market Value Forecast, by Country/Sub-region, 2020-2034
- 15.7.1. Brazil
- 15.7.2. Mexico
- 15.7.3. Rest of Latin America
- 15.8. Market Attractiveness Analysis
- 15.8.1. By Drug Class
- 15.8.2. By Disease Type
- 15.8.3. By Age-Group
- 15.8.4. By Route of Administration
- 15.8.5. By Distribution Channel
- 15.8.6. By Country/Sub-region
16. Middle East & Africa Sickle Cell Disease Treatment Market Analysis and Forecast
- 16.1. Introduction
- 16.2. Market Value Forecast, by Drug Class, 2020-2034
- 16.2.1. Antimetabolites
- 16.2.2. Amino Acids
- 16.2.3. NSAIDs
- 16.2.4. Monoclonal Antibodies
- 16.2.5. Others
- 16.3. Market Value Forecast, by Disease Type, 2020-2034
- 16.3.1. Hemoglobin SS (HbSS)
- 16.3.2. Hemoglobin SC (HbSC)
- 16.3.3. Hemoglobin (HbS) beta thalassemia
- 16.4. Market Value Forecast, by Age-Group, 2020-2034
- 16.4.1. Children
- 16.4.2. Adults
- 16.5. Market Value Forecast, by Route of Administration, 2020-2034
- 16.5.1. Oral
- 16.5.2. Parenteral
- 16.6. Market Value Forecast, by Distribution Channel, 2020-2034
- 16.6.1. Hospital Pharmacies
- 16.6.2. Retail Pharmacies
- 16.6.3. Online Pharmacies
- 16.7. Market Value Forecast, by Country/Sub-region, 2020-2034
- 16.7.1. GCC Countries
- 16.7.2. South Africa
- 16.7.3. Rest of Middle East & Africa
- 16.8. Market Attractiveness Analysis
- 16.8.1. By Drug Class
- 16.8.2. By Disease Type
- 16.8.3. By Age-Group
- 16.8.4. By Route of Administration
- 16.8.5. By Distribution Channel
- 16.8.6. By Country/Sub-region
17. Competition Landscape
- 17.1. Market Player - Competition Matrix (By Tier and Size of companies)
- 17.2. Market Share Analysis, by Company (2023)
- 17.3. Company Profiles
- 17.3.1. Bristol-Myers Squibb Company
- 17.3.1.1. Company Overview
- 17.3.1.2. Financial Overview
- 17.3.1.3. Product Portfolio
- 17.3.1.4. Business Strategies
- 17.3.1.5. Recent Developments
- 17.3.2. Novartis AG
- 17.3.2.1. Company Overview
- 17.3.2.2. Financial Overview
- 17.3.2.3. Product Portfolio
- 17.3.2.4. Business Strategies
- 17.3.2.5. Recent Developments
- 17.3.3. Emmaus Medical, Inc.
- 17.3.3.1. Company Overview
- 17.3.3.2. Financial Overview
- 17.3.3.3. Product Portfolio
- 17.3.3.4. Business Strategies
- 17.3.3.5. Recent Developments
- 17.3.4. Bluebird bio Inc.
- 17.3.4.1. Company Overview
- 17.3.4.2. Financial Overview
- 17.3.4.3. Product Portfolio
- 17.3.4.4. Business Strategies
- 17.3.4.5. Recent Developments
- 17.3.5. Pfizer Inc.
- 17.3.5.1. Company Overview
- 17.3.5.2. Financial Overview
- 17.3.5.3. Product Portfolio
- 17.3.5.4. Business Strategies
- 17.3.5.5. Recent Developments
- 17.3.6. CRISPR Therapeutics
- 17.3.6.1. Company Overview
- 17.3.6.2. Financial Overview
- 17.3.6.3. Product Portfolio
- 17.3.6.4. Business Strategies
- 17.3.6.5. Recent Developments
- 17.3.7. F. Hoffmann-La Roche AG
- 17.3.7.1. Company Overview
- 17.3.7.2. Financial Overview
- 17.3.7.3. Product Portfolio
- 17.3.7.4. Business Strategies
- 17.3.7.5. Recent Developments
- 17.3.8. Vertex Pharmaceuticals Incorporated
- 17.3.8.1. Company Overview
- 17.3.8.2. Financial Overview
- 17.3.8.3. Product Portfolio
- 17.3.8.4. Business Strategies
- 17.3.8.5. Recent Developments
- 17.3.9. Agios Pharmaceuticals, Inc.
- 17.3.9.1. Company Overview
- 17.3.9.2. Financial Overview
- 17.3.9.3. Product Portfolio
- 17.3.9.4. Business Strategies
- 17.3.9.5. Recent Developments
- 17.3.10. GlycoMimetics
- 17.3.10.1. Company Overview
- 17.3.10.2. Financial Overview
- 17.3.10.3. Product Portfolio
- 17.3.10.4. Business Strategies
- 17.3.10.5. Recent Developments
- 17.3.11. Graphite Bio, Inc.
- 17.3.11.1. Company Overview
- 17.3.11.2. Financial Overview
- 17.3.11.3. Product Portfolio
- 17.3.11.4. Business Strategies
- 17.3.11.5. Recent Developments
- 17.3.12. Mylan N.V.
- 17.3.12.1. Company Overview
- 17.3.12.2. Financial Overview
- 17.3.12.3. Product Portfolio
- 17.3.12.4. Business Strategies
- 17.3.12.5. Recent Developments
- 17.3.13. Teva Pharmaceutical Industries Ltd.
- 17.3.13.1. Company Overview
- 17.3.13.2. Financial Overview
- 17.3.13.3. Product Portfolio
- 17.3.13.4. Business Strategies
- 17.3.13.5. Recent Developments
- 17.3.14. AstraZeneca
- 17.3.14.1. Company Overview
- 17.3.14.2. Financial Overview
- 17.3.14.3. Product Portfolio
- 17.3.14.4. Business Strategies
- 17.3.14.5. Recent Developments
- 17.3.15. Hikma Pharmaceuticals PLC
- 17.3.15.1. Company Overview
- 17.3.15.2. Financial Overview
- 17.3.15.3. Product Portfolio
- 17.3.15.4. Business Strategies
- 17.3.15.5. Recent Developments
- 17.3.16. Addmedica
- 17.3.16.1. Company Overview
- 17.3.16.2. Financial Overview
- 17.3.16.3. Product Portfolio
- 17.3.16.4. Business Strategies
- 17.3.16.5. Recent Developments
